Moreover, an increasing trend was observed for administration of higher than prophylactic doses, with regards to the clinical oncology setting (line of systemic anticancer treatment).
← all excerpts
Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
1
—
—